Global, regional, and national burden of cancer in the elderly population, 1990–2021: analysis of data from the Global Burden of Disease Study 2021
Peer-Reviewed Publication
Updates every hour. Last Updated: 14-Dec-2025 02:11 ET (14-Dec-2025 07:11 GMT/UTC)
elderly. This study aims to assess the prevalence, mortality, and disability-adjusted life years (DALY) burden of cancer among individuals aged 60–94 worldwide from 1990 to 2021. Data on the prevalence, mortality, and DALY for 35 cancer types in the elderly were derived from the Global Burden of Disease Study (GBD) spanning 1990 to 2021. The analysis was performed at four stratified levels: global, 21 GBD regions, 204 countries, and five sociodemographic index (SDI) categories. Age-standardized rates for prevalence, mortality, and DALYs were computed. In 2021, the global elderly population (60–94 years) reported 691.13 × 105 [627.13 × 105, 773.82 × 105] cancer cases and 71.86 × 105 [65.07 × 105, 77.31 × 105] cancer deaths, with a DALY total of approximately 1394.17 × 105 [1281.20 × 105, 1495.54 × 105]. Trends indicate a gradual increase in cancer cases and mortality over time, with DALY rates escalating with aging. Notably, high-income North America exhibited the highest age-standardized prevalence. High SDI regions faced the most substantial elderly cancer burden. The burden of cancer among the elderly exhibits considerable variability globally, with developed socioeconomic areas experiencing a greater prevalence than those in underdeveloped regions, necessitating urgent attention from health professionals.
The National Foundation for Cancer Research (NFCR) hosted its 2025 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship on October 24 at the National Press Club, in Washington, D.C., gathering many of the most forward-thinking minds in oncology, cancer research, technology, patient care, and biomedical innovation.
This year’s summit centered on a defining theme: how artificial intelligence (AI) is reshaping the entire ecosystem of cancer research and patient care, from laboratory discovery to bedside decision-making.
Sessions focused on the latest advances in cancer vaccines, immunotherapy and immunology research
Symposium featured a panel discussion with five Nobel laureates, moderated by TIME Senior Health Correspondent Alice Park
Yannik Kaiser, MD-candidate, and Ralph Weissleder, MD, PhD, of the Center for Systems Biology at Massachusetts General Hospital and Harvard Medical School are the lead and corresponding authors of a paper published in Nature Biomedical Engineering, “Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence.”